مباشر

Clinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk Endpoints NewsEli Lilly's claims data deadline may kick off new 340B fight Clinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results AgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.com Endpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapy Clinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EY FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies Endpoints NewsA different approach to lowering healthcare costs CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity Clinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics

BioWorld ٩ يونيو ٢٠٢٦

New 5-HT2C receptor agonists reported in Hansoh patent

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C recept...

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor agonists reported to be potentially useful for the treatment of mood disorders.